Loading...
•
Jun 30, 2022
BioCryst Q2 2022 Earnings Report
Reported second quarter 2022 financial results and provided a corporate update.
Key Takeaways
BioCryst reported total revenues of $65.5 million, driven by $65.2 million in ORLADEYO net revenue. The company's net loss was $58.9 million, or $0.32 per share. Cash, cash equivalents, restricted cash and investments totaled $418.9 million at June 30, 2022.
ORLADEYO net revenue of $65.2 million in Q2 2022.
FY 2022 ORLADEYO net revenue expected to be between $255 million and $265 million.
Research and development expenses increased to $62.0 million.
Cash, cash equivalents, restricted cash and investments totaled $418.9 million at June 30, 2022.
Forward Guidance
The company expects full year 2022 net ORLADEYO revenue to be between $255 million and $265 million. The company now expects operating expenses for full year 2022, not including non-cash stock compensation, to be between $390 million and $400 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...